循证医学-病因学研究和循证医学实践-新-研课件

Evidence-basedEtiology/Harm

病因研究与循证医学实践Evidence-basedEtiology/Harm学习目标掌握评价病因性研究真实性原则(Validity)掌握评价病因性研究重要性原则(Importance)学会应用病因性研究证据的结果，解决临床问题(Applying)学习目标掌握评价病因性研究真实性原则(Validity)病因性研究基本知识病因性研究基本概念与病因相关的临床问题病因性研究的主要方法病因/不良反应研究证据的分级病因性研究常用统计学指标病因性研究基本知识病因性研究基本概念病因性研究基本概念（1）病因是指引起人体发生疾病的原因。病因学是指研究疾病病因的科学。病因：致病因素（直接、间接、危险因素）研究内容：用流行病学方法研究并验证危险因素是否与疾病发生有因果关系，且评估因果联系的强弱。例“吸烟与肺癌关系”病因性研究基本概念（1）病因是指引起人体发生疾病的原因。病因病因性研究基本概念（2）不良反应的研究实质上也是病因学研究

“因”：造成不良反应的各种因素，如各种治疗措施（药物，手术）医疗过程中临床医师经常需要考虑某种危险因素或治疗措施是否对患者有害。利是否大于弊？用他人的研究结果来回答提出的问题

真实性重要性实用性病因性研究基本概念（2）不良反应的研究实质上也是病因学研究与病因相关的临床问题该疾病是什么原因造成的？该药物或治疗措施会导致什么不良反应吗？是否需要停药？DoesexposuretoaluminumcauseAlzheimer’sdementia?Dostatinscausecancer?与病因相关的临床问题该疾病是什么原因造成的？病因性研究的主要方法病因性研究的主要方法病因性研究常用统计学指标因果相关性强度的指标RR(前瞻性)RCT,cohortstudyOR(回顾性）case-controlstudyNNH(numberneededtoharm)clinicalimportance暴露多少研究对象可导致1例发病（队列研究）发生1例不良反应所需治疗的病例数（临床研究）病因性研究常用统计学指标因果相关性强度的指标因果相关性强度的指标当所研究疾病的发病率较低时，OR近似于RR，故在回顾性研究中可用OR估计RR,其解释与RR同，易于统计分析RR或OR愈高，则因果关系强度愈强RR或OR有多大才有意义，无一定的标准1.2-1.5:弱联系1.6-2.9:中等联系

>3.0:强联系因果相关性强度的指标当所研究疾病的发病率较低时，OR近似于R可信区间ConfidenceInterval因果关系的强度外，评价精确度按一定的概率去估计总体参数所在的范围95％的可信区间循证医学－估计总体参数－假设检验：RR可信区间ConfidenceInterval因果关系的强度有关指标的计算1.OddsRatio

2.RelativeRisk3.RiskReduction/Increase

4.NumberNeededtoTreat/Harm

有关指标的计算1.OddsRatio2.Relati循证医学_病因学研究和循证医学实践_新_研课件證據的強度證據的強度TheConfusionMatrix+veEvent-veEventTotalExperimentABA+ＢControlCDC+DAlsoknownasthe2x2tableTheConfusionMatrix+veEvent-EventRateEER=A/(A+B)

试验组事件发生率CER=C/(C+D)

对照组事件发生率+veEvent-veEventTotalExperimentABA+ＢControlCDC+DEventRateEER=A/(A+B)+veERRandORRR=EER/CER

相对危险度OR=AD/BC

比值比+veEvent-veEventTotalExperimentABA+ＢControlCDC+DRRandORRR=EER/CER+veEveRelativeRiskReductionRRR=(CER-EER)/CER

=1–RR

相对危险度减少率+veEvent-veEventTotalExperimentABA+ＢControlCDC+DRelativeRiskReductionRRR=(C(Absolute)RiskReductionARR=CER-EER绝对危险度减少率+veEvent-veEventTotalExperimentABA+ＢControlCDC+D(Absolute)RiskReductionARR=NumberNeededtoTreatNNT =1/ARR得到1例有利结果需要防治的病例数+veEvent-veEventTotalExperimentABA+ＢControlCDC+DNumberNeededtoTreatNNT =1举例：

ActivatedProteinCforSevereSepsisBleedNobleedTotalAPC30820850Control17823840APC=ActivatedProteinCEfficacyandsafetyofrecombinanthumanactivatedproteinCforseveresepsis.NEnglJMed.2001Mar8;344(10):699-709举例：

ActivatedProteinCforSeEventRatesandOddsEER =A/(A+B) =30/850=0.035CER =C/(C+D) =17/840=0.020EEO=A/B =30/820=0.037CEO=C/D =17/823=0.021+veEvent-veEventTotalExperimentABA+ＢControlCDC+DBleedNobleedTotalAPC30820850Control17823840OR =EEO/CEO =0.037/0.021=1.77RR =EER/CER =0.035/0.020=1.744RRI =(EER–CER)/CER =0.015/0.020=0.744 =74%ARI =EER–CER =0.035–0.020=0.015

NNH =1/ARI =66EventRatesandOddsEER =A/Risk-BenefitRatioNNT =1/ARR=1/0.06 =16(治疗16个获益1个：存活)

反映有利结果（越小越好）NNH =1/ARI=1/0.015 =66(治疗66个损害1个：严重出血)

反映不良反应（越大越好）Risk-BenefitRatio =NNT/NNH =16/66 =1/4DeadNotdeadTotalAPC210640850Control259581840BleedNobleedTotalAPC30820850Control17823840Risk-BenefitRatioNNT =1/A怎样解决临床问题？

Howtosolveaclinicalproblem?怎样解决临床问题？

Howtosolveaclini临床病案（ClinicalScenario）84岁的男性，近期记忆力明显下降.高血压病，高胆固醇血症。右眼白内障术后2天，出现易激、谵妄和性格改变。无感染，贫血及代谢异常的临床证据。心理卫生中心会诊：抗精神病药物氟哌啶醇,haloperidol,奋乃静perphenazine,奥氮平,olanzapine临床病案（ClinicalScenario）84岁的男性，临床问题（InitialQuestion）老年患者中，用传统性抗精神病药物（如氟哌啶醇,haloperidol,奋乃静perphenazine,）是否会增加死亡风险性？非典型性抗精神病药物(如奥氮平,olanzapine,）是否对老年人更安全？临床问题（InitialQuestion）老年患者中，用传第一步提出问题(AskClinicalQuestions)Initialquestion:Framingtheinitialquestion:answerablePatients(population)Intervention/exposureComparisonOutcomePICO第一步提出问题(AskClinicalQuestion转变成可以回答的临床问题

Framingthequestion患者类型(P)elderlypatients干预措施(I)haloperidolorperphenazine对照措施(C)olanzapine临床结局(O)death转变成可以回答的临床问题

Framingthequest第二步查询证据(AcquireEvidence)PICO:keywordsTypeofquestion：harm-Bestevidence

Levelsofevidence-OptimalsourceofevidenceSearchingworthwhile?第二步查询证据(AcquireEvidence)PIC病因/不良反应研究常用数据库BestEvidence（ACPjournalclub,EBM)UptoDateMedlinePubMed:clinicalquery-etiologySumsearchOvid循证医学数据库(多库同时检索)ACPjournalclub,CochraneLibrary(CDSR,CCTR,DARE),Medline,EMBASE病因/不良反应研究常用数据库BestEvidence（AC系统评价资料库(CochraneDatabaseofSystematicReview,CDSR)疗效评价文摘库(DatabaseofAbstractsofReviewsofEffectiveness,DARE)临床对照试验注册资料库(CochraneControlledTrialsRegister,CCTR)方法学数据库(CochraneMethodologyDatabase)系统评价资料库(CochraneDatabaseofS检索方法选择数据库：ACPjournalclub（oviddatabase,bestevidence）在search中，键入关键词olanzapine－etiology（病因学）检索结果：1篇文献（摘要）找到全文检索方法选择数据库：ACPjournalclub（ovi循证医学_病因学研究和循证医学实践_新_研课件循证医学_病因学研究和循证医学实践_新_研课件筛选结果ACPjournalClubsummary:ConventionalantipsychoticdrugsincreasedriskfordeathmorethandidatypicalantipsychoticdrugsinelderlypatientsACPJournalClub.2007;147:23.SchneeweissS,SetoguchiS,BrookhartA,DormuthC,WangPS.Riskofdeathassociatedwiththeuseofconventionalversusatypicalantipsychoticdrugsamongelderlypatients.CMAJ.2007;176:627-32筛选结果ACPjournalClubsummary:循证医学_病因学研究和循证医学实践_新_研课件研究详情Background:Publichealthadvisorieshavewarnedthattheuseofatypicalantipsychoticmedicationsincreasestheriskofdeathamongelderlypatients.Weassessedtheshort-termmortalityinapopulation-basedcohortofelderlypeopleinBritishColumbiawhowereprescribedconventionalandatypicalantipsychoticmedications.Methods:WeusedlinkedhealthcareutilizationdataofallBCresidentstoidentifyacohortofpeopleaged65years

andolderwhobegantakingantipsychoticmedicationsbetweenJanuary1996andDecember2004andwerefreeofcancer.Wecomparedthe180-dayall-causemortalitybetweenresidentstakingconventionalantipsychoticmedicationsandthosetakingatypicalantipsychoticmedications.

研究详情Background:PublichealthResults:Of37241elderlypeopleinthestudycohort,12882wereprescribedaconventionalantipsychoticmedicationand24359anatypicalformulation.Withinthefirst180daysofuse,1822patients(14.1%)intheconventionaldruggroupdied,comparedwith2337(9.6%)intheatypicaldruggroup(mortalityratio1.47,95%confidenceinterval[CI]1.39–1.56).Multivariableadjustmentresultedina180-daymortalityratioof1.32(1.23–1.42).Incomparisonwithrisperidone（利培酮）,haloperidol（氟哌啶醇）wasassociatedwiththegreatestincreaseinmortality(mortalityratio

2.14,95%CI1.86–2.45)andloxapine（洛沙平）thelowest(mortalityratio1.29,95%CI1.19–1.40).Thegreatestincreaseinmortalityoccurredamongpeopletakinghigher(abovemedian)dosesofconventionalantipsychoticmedications(mortalityratio1.67,95%CI1.50–1.86)andduringthefirst40daysafterthestartofdrugtherapy(mortalityratio1.60,95%CI1.42–1.80).Resultswereconfirmedinpropensityscoreanalysesandinstrumentalvariableestimation,minimizingresidualconfounding.Results:Of37241elderlypeop结论Interpretation:Amongelderlypatients,theriskofdeathassociatedwithconventionalantipsychoticmedicationsiscomparabletoandpossiblygreaterthantheriskofdeathassociatedwithatypicalantipsychoticmedications.Untilfurtherevidenceisavailable,physiciansshouldconsiderallantipsychoticmedicationstobeequallyriskyinelderlypatients.结论Interpretation:Amongelderl第三步评价证据AppraiseEvidence证据的真实性Aretheresultsvalid?证据的重要性Whataretheresults?第三步评价证据AppraiseEvidence证据的真证据的真实性

Aretheresultsvalid?证据的真实性

Aretheresultsvalid?1研究方法的论证强度

TypeofReportsonEtiology/Harm哪种研究方法？论证强度如何？是否源于真正的人体试验？

Werethereclearlydefinedgroupsofpatients,similarinallimportantwaysotherthanexposuretothetreatmentorothercause?1研究方法的论证强度

TypeofReportson本研究Objective:Inelderlypatients,associationofconventionaloratypicalantipsychoticdrugs(APDs)withdeath?Design:CohortstudyParticipants:37241patients65yofageoralconventional(n=12882,meanage80y)

atypical(n=24359,meanage80y).Exclusioncriteria:canceranduseofAPDsintheyearbeforetheindexdate.本研究Objective:Inelderlypatie2两组结局暴露因素的测量方法是否一致？Weretreatments/exposuresandclinicaloutcomesmeasuredinthesamewaysinbothgroups?(Wastheassessmentofoutcomeseitherobjectiveorblindedtoexposure?)Weretheoutcomesandexposuresmeasuredinthesamewayinthegroupsbeingcompared?2两组结局暴露因素的测量方法是否一致？WeretreatCohortStudySurveillancebias:监测偏倚偏倚的控制－客观指标（Objectiveoutcome）：病死率－主观指标（Subjectiveoutcome）:Blinding举例：乙型肝炎与肝癌关系的研究

CohortStudySurveillancebias:3.随访时间及失访率Wasthefollow-upofthestudypatientssufficientlylong(fortheoutcometooccur)andcomplete?举例：HP与胃癌：5年（无差异），10

年（显著差异）失访超过20％？--结果将失去真实性3.随访时间及失访率Wasthefollow-upo4病因/不良反应研究结果是否符合病因诊断原则Dotheresultsoftheharmstudysatisfysomeofthediagnostictestsforcausation?4病因/不良反应研究结果是否符合病因诊断原则DotheIsitclearthattheexposureprecededtheonsetoftheoutcome?

因果效应的先后顺序－仅见于前瞻性研究Isthereadose–responsegradient?

因果效应的相关程度，剂量依赖（吸烟与肺癌）Isthereanypositiveevidencefroma

“dechallenge–rechallenge”

study?

符合流行病学规律-危险因素减弱，发病减少IsitclearthattheexposureIstheassociationconsistentfromstudytostudy?

不同研究，结果一致（HP与胃癌）Doestheassociationmakebiologicalsense?

充分的生物学依据（CCB与癌症，坏血病与水果蔬菜）IstheassociationconsistentKeyPoints1.Werethereclearlydefinedgroupsofpatients,similarinallimportantwaysotherthanexposuretothetreatmentorothercause?

研究方法的论证强度2.Weretreatments/exposuresandclinicaloutcomesmeasuredinthesamewaysinbothgroups?

测量方法一致3.Wasthefollow-upofthestudypatientssufficientlylong(fortheoutcometooccur)andcomplete?

随访时间及失访率KeyPoints1.Werethereclearl证据的重要性

Whataretheresults?证据的重要性

Whataretheresults?1.因果联系强度Whatisthemagnitudeoftheassociationbetweentheexposureandoutcome?Howstrongistheassociationbetweenexposureandoutcome?RR

ORNNH1.因果联系强度Whatisthemagnitude2.结果是否准确？Whatistheprecisionoftheestimateoftheassociationbetweentheexposureandoutcome?Howpreciseistheestimateofrisk?95%CI2.结果是否准确？WhatistheprecisioConventionalAPDvsAtypicalAPD

AssociationwithdeathConventionalAPDvsAtypicalA第四步应用证据

HowcanIapplytheresultstomypatient?第四步应用证据

HowcanIapplythere病情相似Isourpatientsodifferentfromthoseincludedinthestudythatitsresultscannotapply?Werethestudypatientssimilartomypatient?基于纳入和排除标准病情相似Isourpatientsodifferen本研究Patients:>65yofage,60-65%womenUsed1medicalservice,andfilled1prescriptioninthetwo6-monthintervalsbeforetheindexdate.Exclusioncriteria:canceranduseofAPDsintheyearbeforetheindexdate.AtypicalAPDs:risperidone,quetiapine,olanzapine,andclozapineConventionalAPDs:loxapine,haloperidol,chlorpromazine,trifluoperazine,thioridazine,pimozide,promazine,perphenazine,fluphenazine,mesoridazine,andthiothixene.本研究Patients:>65yofage,6权衡利弊Whatisourpatient’sriskofbenefitandharmfromtheagent?NNTandNNH权衡利弊Whatisourpatient’srisk举例一项心律失常抑制试验（CAST):

恩卡尼/氟卡尼与安慰剂：10月随访，病死率分别为7.7%和3.0%，NNH＝21（平均每21个患者服此药，将有1人发生额外死亡）NSIAD与消化道出血：NNH＝2000（每2000

人服NSAIDs，预期增加1例消化道出血患者）举例一项心律失常抑制试验（CAST):本病案使用传统和非典型性抗精神病药物

NNT/NNH

作者未进行计算和分析查询其他证据本病案使用传统和非典型性抗精神病药物患者的价值观和愿望Whatareourpatient’spreferences,concerns,andexpectationsfromthistreatment?1、为了避免疾病的进展而接受治疗，可能带来不良反应

2、宁愿冒疾病进展的风险而不接受治疗

3、关注费用

4、无所谓的态度患者的价值观和愿望Whatareourpatient’其他可替代的疗法Whatalternativetreatmentsareavailable?---当危险因素或治疗措施的危险明确而且巨大，则应立即脱离危险因素或终止治疗。举例

β-blockersforhypertensioninpatientswithasthma

治疗高血压的β受体阻滞剂能加重支气管痉挛；血管紧张素转换酶抑制剂巯甲丙脯酸、依那普利等，既能降压，又不诱发支气管痉挛，其他可替代的疗法Whatalternativetreat本病案：临床决策对该患者选择哪类抗精神病药?本病案：临床决策对该患者选择哪类抗精神病药?Evidence-basedpracticeinrealtime直接查询已经评价过的高质量的综合临床证据(preappraisedevidence)，如选择数据库“ACPjournalclub”,“临床证据”（clinicalevidence，）等进行查询。这些信息资源一般收集高质量且临床实用性强的研究，已经对某种病因性研究的价值进行了总结。使用已评价过的高质量证据，临床医师可在30秒内找到拟解决问题的答案，特别适用于在床旁实践循证医学Evidence-basedpracticeinrea知识回顾KnowledgeReview知识回顾KnowledgeReviewEvidence-basedEtiology/Harm

病因研究与循证医学实践Evidence-basedEtiology/Harm学习目标掌握评价病因性研究真实性原则(Validity)掌握评价病因性研究重要性原则(Importance)学会应用病因性研究证据的结果，解决临床问题(Applying)学习目标掌握评价病因性研究真实性原则(Validity)病因性研究基本知识病因性研究基本概念与病因相关的临床问题病因性研究的主要方法病因/不良反应研究证据的分级病因性研究常用统计学指标病因性研究基本知识病因性研究基本概念病因性研究基本概念（1）病因是指引起人体发生疾病的原因。病因学是指研究疾病病因的科学。病因：致病因素（直接、间接、危险因素）研究内容：用流行病学方法研究并验证危险因素是否与疾病发生有因果关系，且评估因果联系的强弱。例“吸烟与肺癌关系”病因性研究基本概念（1）病因是指引起人体发生疾病的原因。病因病因性研究基本概念（2）不良反应的研究实质上也是病因学研究

“因”：造成不良反应的各种因素，如各种治疗措施（药物，手术）医疗过程中临床医师经常需要考虑某种危险因素或治疗措施是否对患者有害。利是否大于弊？用他人的研究结果来回答提出的问题

真实性重要性实用性病因性研究基本概念（2）不良反应的研究实质上也是病因学研究与病因相关的临床问题该疾病是什么原因造成的？该药物或治疗措施会导致什么不良反应吗？是否需要停药？DoesexposuretoaluminumcauseAlzheimer’sdementia?Dostatinscausecancer?与病因相关的临床问题该疾病是什么原因造成的？病因性研究的主要方法病因性研究的主要方法病因性研究常用统计学指标因果相关性强度的指标RR(前瞻性)RCT,cohortstudyOR(回顾性）case-controlstudyNNH(numberneededtoharm)clinicalimportance暴露多少研究对象可导致1例发病（队列研究）发生1例不良反应所需治疗的病例数（临床研究）病因性研究常用统计学指标因果相关性强度的指标因果相关性强度的指标当所研究疾病的发病率较低时，OR近似于RR，故在回顾性研究中可用OR估计RR,其解释与RR同，易于统计分析RR或OR愈高，则因果关系强度愈强RR或OR有多大才有意义，无一定的标准1.2-1.5:弱联系1.6-2.9:中等联系

>3.0:强联系因果相关性强度的指标当所研究疾病的发病率较低时，OR近似于R可信区间ConfidenceInterval因果关系的强度外，评价精确度按一定的概率去估计总体参数所在的范围95％的可信区间循证医学－估计总体参数－假设检验：RR可信区间ConfidenceInterval因果关系的强度有关指标的计算1.OddsRatio

2.RelativeRisk3.RiskReduction/Increase

4.NumberNeededtoTreat/Harm

有关指标的计算1.OddsRatio2.Relati循证医学_病因学研究和循证医学实践_新_研课件證據的強度證據的強度TheConfusionMatrix+veEvent-veEventTotalExperimentABA+ＢControlCDC+DAlsoknownasthe2x2tableTheConfusionMatrix+veEvent-EventRateEER=A/(A+B)

试验组事件发生率CER=C/(C+D)

对照组事件发生率+veEvent-veEventTotalExperimentABA+ＢControlCDC+DEventRateEER=A/(A+B)+veERRandORRR=EER/CER

相对危险度OR=AD/BC

比值比+veEvent-veEventTotalExperimentABA+ＢControlCDC+DRRandORRR=EER/CER+veEveRelativeRiskReductionRRR=(CER-EER)/CER

=1–RR

相对危险度减少率+veEvent-veEventTotalExperimentABA+ＢControlCDC+DRelativeRiskReductionRRR=(C(Absolute)RiskReductionARR=CER-EER绝对危险度减少率+veEvent-veEventTotalExperimentABA+ＢControlCDC+D(Absolute)RiskReductionARR=NumberNeededtoTreatNNT =1/ARR得到1例有利结果需要防治的病例数+veEvent-veEventTotalExperimentABA+ＢControlCDC+DNumberNeededtoTreatNNT =1举例：

ActivatedProteinCforSevereSepsisBleedNobleedTotalAPC30820850Control17823840APC=ActivatedProteinCEfficacyandsafetyofrecombinanthumanactivatedproteinCforseveresepsis.NEnglJMed.2001Mar8;344(10):699-709举例：

ActivatedProteinCforSeEventRatesandOddsEER =A/(A+B) =30/850=0.035CER =C/(C+D) =17/840=0.020EEO=A/B =30/820=0.037CEO=C/D =17/823=0.021+veEvent-veEventTotalExperimentABA+ＢControlCDC+DBleedNobleedTotalAPC30820850Control17823840OR =EEO/CEO =0.037/0.021=1.77RR =EER/CER =0.035/0.020=1.744RRI =(EER–CER)/CER =0.015/0.020=0.744 =74%ARI =EER–CER =0.035–0.020=0.015

NNH =1/ARI =66EventRatesandOddsEER =A/Risk-BenefitRatioNNT =1/ARR=1/0.06 =16(治疗16个获益1个：存活)

反映有利结果（越小越好）NNH =1/ARI=1/0.015 =66(治疗66个损害1个：严重出血)

反映不良反应（越大越好）Risk-BenefitRatio =NNT/NNH =16/66 =1/4DeadNotdeadTotalAPC210640850Control259581840BleedNobleedTotalAPC30820850Control17823840Risk-BenefitRatioNNT =1/A怎样解决临床问题？

Howtosolveaclinicalproblem?怎样解决临床问题？

Howtosolveaclini临床病案（ClinicalScenario）84岁的男性，近期记忆力明显下降.高血压病，高胆固醇血症。右眼白内障术后2天，出现易激、谵妄和性格改变。无感染，贫血及代谢异常的临床证据。心理卫生中心会诊：抗精神病药物氟哌啶醇,haloperidol,奋乃静perphenazine,奥氮平,olanzapine临床病案（ClinicalScenario）84岁的男性，临床问题（InitialQuestion）老年患者中，用传统性抗精神病药物（如氟哌啶醇,haloperidol,奋乃静perphenazine,）是否会增加死亡风险性？非典型性抗精神病药物(如奥氮平,olanzapine,）是否对老年人更安全？临床问题（InitialQuestion）老年患者中，用传第一步提出问题(AskClinicalQuestions)Initialquestion:Framingtheinitialquestion:answerablePatients(population)Intervention/exposureComparisonOutcomePICO第一步提出问题(AskClinicalQuestion转变成可以回答的临床问题

Framingthequestion患者类型(P)elderlypatients干预措施(I)haloperidolorperphenazine对照措施(C)olanzapine临床结局(O)death转变成可以回答的临床问题

Framingthequest第二步查询证据(AcquireEvidence)PICO:keywordsTypeofquestion：harm-Bestevidence

Levelsofevidence-OptimalsourceofevidenceSearchingworthwhile?第二步查询证据(AcquireEvidence)PIC病因/不良反应研究常用数据库BestEvidence（ACPjournalclub,EBM)UptoDateMedlinePubMed:clinicalquery-etiologySumsearchOvid循证医学数据库(多库同时检索)ACPjournalclub,CochraneLibrary(CDSR,CCTR,DARE),Medline,EMBASE病因/不良反应研究常用数据库BestEvidence（AC系统评价资料库(CochraneDatabaseofSystematicReview,CDSR)疗效评价文摘库(DatabaseofAbstractsofReviewsofEffectiveness,DARE)临床对照试验注册资料库(CochraneControlledTrialsRegister,CCTR)方法学数据库(CochraneMethodologyDatabase)系统评价资料库(CochraneDatabaseofS检索方法选择数据库：ACPjournalclub（oviddatabase,bestevidence）在search中，键入关键词olanzapine－etiology（病因学）检索结果：1篇文献（摘要）找到全文检索方法选择数据库：ACPjournalclub（ovi循证医学_病因学研究和循证医学实践_新_研课件循证医学_病因学研究和循证医学实践_新_研课件筛选结果ACPjournalClubsummary:ConventionalantipsychoticdrugsincreasedriskfordeathmorethandidatypicalantipsychoticdrugsinelderlypatientsACPJournalClub.2007;147:23.SchneeweissS,SetoguchiS,BrookhartA,DormuthC,WangPS.Riskofdeathassociatedwiththeuseofconventionalversusatypicalantipsychoticdrugsamongelderlypatients.CMAJ.2007;176:627-32筛选结果ACPjournalClubsummary:循证医学_病因学研究和循证医学实践_新_研课件研究详情Background:Publichealthadvisorieshavewarnedthattheuseofatypicalantipsychoticmedicationsincreasestheriskofdeathamongelderlypatients.Weassessedtheshort-termmortalityinapopulation-basedcohortofelderlypeopleinBritishColumbiawhowereprescribedconventionalandatypicalantipsychoticmedications.Methods:WeusedlinkedhealthcareutilizationdataofallBCresidentstoidentifyacohortofpeopleaged65years

andolderwhobegantakingantipsychoticmedicationsbetweenJanuary1996andDecember2004andwerefreeofcancer.Wecomparedthe180-dayall-causemortalitybetweenresidentstakingconventionalantipsychoticmedicationsandthosetakingatypicalantipsychoticmedications.

研究详情Background:PublichealthResults:Of37241elderlypeopleinthestudycohort,12882wereprescribedaconventionalantipsychoticmedicationand24359anatypicalformulation.Withinthefirst180daysofuse,1822patients(14.1%)intheconventionaldruggroupdied,comparedwith2337(9.6%)intheatypicaldruggroup(mortalityratio1.47,95%confidenceinterval[CI]1.39–1.56).Multivariableadjustmentresultedina180-daymortalityratioof1.32(1.23–1.42).Incomparisonwithrisperidone（利培酮）,haloperidol（氟哌啶醇）wasassociatedwiththegreatestincreaseinmortality(mortalityratio

2.14,95%CI1.86–2.45)andloxapine（洛沙平）thelowest(mortalityratio1.29,95%CI1.19–1.40).Thegreatestincreaseinmortalityoccurredamongpeopletakinghigher(abovemedian)dosesofconventionalantipsychoticmedications(mortalityratio1.67,95%CI1.50–1.86)andduringthefirst40daysafterthestartofdrugtherapy(mortalityratio1.60,95%CI1.42–1.80).Resultswereconfirmedinpropensityscoreanalysesandinstrumentalvariableestimation,minimizingresidualconfounding.Results:Of37241elderlypeop结论Interpretation:Amongelderlypatients,theriskofdeathassociatedwithconventionalantipsychoticmedicationsiscomparabletoandpossiblygreaterthantheriskofdeathassociatedwithatypicalantipsychoticmedications.Untilfurtherevidenceisavailable,physiciansshouldconsiderallantipsychoticmedicationstobeequallyriskyinelderlypatients.结论Interpretation:Amongelderl第三步评价证据AppraiseEvidence证据的真实性Aretheresultsvalid?证据的重要性Whataretheresults?第三步评价证据AppraiseEvidence证据的真证据的真实性

Aretheresultsvalid?证据的真实性

Aretheresultsvalid?1研究方法的论证强度

TypeofReportsonEtiology/Harm哪种研究方法？论证强度如何？是否源于真正的人体试验？

Werethereclearlydefinedgroupsofpatients,similarinallimportantwaysotherthanexposuretothetreatmentorothercause?1研究方法的论证强度

TypeofReportson本研究Objective:Inelderlypatients,associationofconventionaloratypicalantipsychoticdrugs(APDs)withdeath?Design:CohortstudyParticipants:37241patients65yofageoralconventional(n=12882,meanage80y)

atypical(n=24359,meanage80y).Exclusioncriteria:canceranduseofAPDsintheyearbeforetheindexdate.本研究Objective:Inelderlypatie2两组结局暴露因素的测量方法是否一致？Weretreatments/exposuresandclinicaloutcomesmeasuredinthesamewaysinbothgroups?(Wastheassessmentofoutcomeseitherobjectiveorblindedtoexposure?)Weretheoutcomesandexposuresmeasuredinthesamewayinthegroupsbeingcompared?2两组结局暴露因素的测量方法是否一致？WeretreatCohortStudySurveillancebias:监测偏倚偏倚的控制－客观指标（Objectiveoutcome）：病死率－主观指标（Subjectiveoutcome）:Blinding举例：乙型肝炎与肝癌关系的研究

CohortStudySurveillancebias:3.随访时间及失访率Wasthefollow-upofthestudypatientssufficientlylong(fortheoutcometooccur)andcomplete?举例：HP与胃癌：5年（无差异），10

年（显著差异）失访超过20％？--结果将失去真实性3.随访时间及失访率Wasthefollow-upo4病因/不良反应研究结果是否符合病因诊断原则Dotheresultsoftheharmstudysatisfysomeofthediagnostictestsforcausation?4病因/不良反应研究结果是否符合病因诊断原则DotheIsitclearthattheexposureprecededtheonsetoftheoutcome?

因果效应的先后顺序－仅见于前瞻性研究Isthereadose–responsegradient?

因果效应的相关程度，剂量依赖（吸烟与肺癌）Isthereanypositiveevidencefroma

“dechallenge–rechallenge”

study?

符合流行病学规律-危险因素减弱，发病减少IsitclearthattheexposureIstheassociationconsistentfromstudytostudy?

不同研究，结果一致（HP与胃癌）Doestheassociationmakebiologicalsense?

充分的生物学依据（CCB与癌症，坏血病与水果蔬菜）IstheassociationconsistentKeyPoints1.Werethereclearlydefinedgroupsofpatients,similarinallimportantwaysotherthanexposuretothetreatmentorothercause?

研究方法的论证强度2.Weretreatments/exposuresandclinicaloutcomesmeasuredinthesamewaysinbothgroups?

测量方法一致3.Wast